Astellas Takes Option on Audax IL12 Fusion

Company Astellas; Audax Biosciences Event Type Exclusive option and license Modality Antibody-IL-12 cytokine fusion Asset DAX-044 Target IL-12 (tumor-directed) Disease Area Solid tumors (immuno-oncology) Summary Astellas and Australia-based Audax announced an exclusive worldwide option and license for preclinical DAX-044 on 28 October. The disclosed potential…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline
US Cooperative Group Will Test Ivonescimab in Biliary Cancer